A global SaaS (News - Alert) CRM solutions agreement has been signed by Cegedim Dendrite, the world's premier provider of life-sciences specific CRM solutions and biopharmaceutical company, UCB. 

Being a global biopharmaceutical company, UCB is dedicated to the research and development of innovative medicines for severe diseases in two therapeutic areas - central nervous system and Immunology.

Cegedim Dendrite's flagship CRM solution, Mobile Intelligence will be soon implemented by UCB.

"It is exciting to support UCB in its patient-centric strategy. It proves the extended flexibility of the Cegedim Dendrite offering enables us to perfectly fit with new commercial models in the biopharmaceutical industry," said Laurent Labrune, Cegedim Dendrite CEO.

To support international companies in building their CRM strategies around the world, Mobile Intelligence, available in SaaS single or multi-tenant, Mobile Intelligence, is the only biopharmaceutical specific CRM solution that can be scalable following a hierarchical model on a global, regional and national scale.

In related news, Cegedim Dendrite, has entered into a five-year framework agreement with Pierre Fabre Laboratories, to strengthen and roll-out medical sales solutions to their international subsidiaries.